Breaking News Instant updates and real-time market news.

INSM

Insmed

$24.64

-1.55 (-5.92%)

10:30
08/06/18
08/06
10:30
08/06/18
10:30

Before the Move: Watch Insmed ahead of FDA committee vote on ALIS

JMP Securities analyst Liisa Bayko downgraded Insmed (INSM) to Market Perform ahead of an FDA advisory meeting scheduled for this week, saying she has less confidence in Amikacin Liposome Inhalation Suspension after hosting a call with an ex-FDA Division Director who confirmed some of her concerns. Still bullish on the stock, her peer at H.C. Wainwright argued that the collective strength of ALIS data "essentially removes the regulatory risks." ADCOM MEETING: On Tuesday, the Food and Drug Administration's Antimicrobial Drugs Advisory Committee will discuss new drug application 207356, amikacin liposome inhalation suspension, sponsored by Insmed for the proposed indication of treatment of nontuberculous mycobacterial lung disease caused by mycobacterium avium complex in adults as part of a combination antibacterial drug regimen. JMP SECURITIES MOVING TO THE SIDELINES: JMP Securities' Bayko downgraded Insmed to Market Perform from Outperform after lowering her probability of success for ALIS to 60% from 80%. The analyst said that she has less confidence in ALIS after hosting a call last week with Lee Simon, an ex-FDA Division Director, who confirmed some concerns she had and "pointed out a few new insights" that left Bayko feeling more cautious. Simon discussed the lack of clinical benefit and high rate of adverse events, including 57% more hospitalizations on ALIS + GBT versus GBT alone, she noted. Simon admitted, however, that the outcome was hard to predict because of FDA's desire to bring drugs to market in areas of high unmet medical need. Regardless, Bayko thinks the panel may want to see longer-term data off treatment that could be addressed by the INS-312 extension, which is no longer referred to as examining the "confirmatory" endpoint, but rather as showing durability of effect. Any delay would be viewed as a setback, and one that would be costly given that the sales force is in place and ready to roll, she argued. POSITIVE ADCOM EXPECTED BY WAINWRIGHT: In a research note last week, H.C. Wainwright analyst Andrew Fein said he remained bullish on Insmed as he continues to believe the "collective strength" of the ALIS data essentially removes the regulatory risks, based on high unmet needs in the existing NTM space as no effective treatment is available and the FDA's motivation to address the unmet needs in the NTM treatment. Orphan, QIDP, and breakthrough designations should facilitate ongoing dialogue between the company and the FDA, allowing for few AdCom surprises, and, ultimately, a final approval of ALIS via Subpart-H, Fein told investors. He believes the AdCom could serve as an important positive catalyst for Insmed, and should the committee vote overwhelmingly in favor of the approvability of the Insmed application, the long simmering M&A thesis for the company is likely to shift to the front burner. The analyst reiterated a Buy rating and a $35 price target on the shares, adding that if he were to assume a 100% probability of success for ALIS, he "could easily justify" a valuation north of $50 per share. PRICE ACTION: In morning trading, shares of Insmed have dropped 8% to $24.03. "Before the Move" is The Fly's recurring series of exclusive stories that identify potentially market moving events, along with analyst predictions, ahead of the news.

  • 07

    Aug

  • 28

    Sep

INSM Insmed
$24.64

-1.55 (-5.92%)

08/06/18
08/06/18
DOWNGRADE

Market Perform
Insmed downgraded to Market Perform ahead of AdComm vote at JMP Securities
As previously reported, JMP Securities analyst Liisa Bayko downgraded Insmed to Market Perform from Outperform as she has less confidence in Amikacin Liposome Inhalation Suspension after hosting a call last week with Dr. Lee Simon, an ex-FDA Division Director, who confirmed some concerns she had and "pointed out a few new insights" that left Bayko feeling more cautious. Following her call with the regulatory expert, and ahead of the FDA Advisory Committee meeting on Tuesday, Bayko lowered her odds on the probability of success for ALIS to 60% from 80%.
08/06/18
JMPS
08/06/18
DOWNGRADE
JMPS
Market Perform
Insmed downgraded to Market Perform from Outperform at JMP Securities
08/03/18
HCWC
08/03/18
NO CHANGE
Target $35
HCWC
Buy
H.C. Wainwright bullish on Insmed into Tuesday's FDA panel
H.C. Wainwright analyst Andrew Fein is bullish on shares of Insmed into Tuesday's FDA panel meeting. The collective strength of the Amikacin Liposome Inhalation Suspension data "essentially removes the regulatory risks," Fein tells investors in a research note. With no effective treatment available, the analyst expects a positive panel vote. He reiterates a Buy rating on Insmed with a $35 price target. The analyst adds that if he were to assume a 100% probability of success for ALIS, he "could easily justify" a valuation north of $50 per share.
07/23/18
GSCO
07/23/18
INITIATION
Target $32
GSCO
Neutral
Insmed initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Dana Flanders started Insmed with a Neutral rating and $32 price target. The analyst is taking a more conservative stance on the initial launch of Alis relative to consensus estimates. Flanders does, however, see a high unmet need in treating nontuberculous mycobacterial lung disease.

TODAY'S FREE FLY STORIES

TLRD

Tailored Brands

$7.66

-0.41 (-5.08%)

13:05
03/20/19
03/20
13:05
03/20/19
13:05
Options
Tailored Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$29.13

-3.5 (-10.73%)

12:55
03/20/19
03/20
12:55
03/20/19
12:55
Options
Health Insurance Innovations put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

DRI

Darden

$108.53

-1.88 (-1.70%)

, CAG

Conagra Brands

$22.72

-0.09 (-0.39%)

12:53
03/20/19
03/20
12:53
03/20/19
12:53
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

DRI

Darden

$108.53

-1.88 (-1.70%)

CAG

Conagra Brands

$22.72

-0.09 (-0.39%)

CMC

Commercial Metals

$15.86

-0.26 (-1.61%)

GIII

G-III Apparel

$34.73

-0.83 (-2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

MU

Micron

$39.75

-0.63 (-1.56%)

, WSM

Williams-Sonoma

$56.40

-0.39 (-0.69%)

12:53
03/20/19
03/20
12:53
03/20/19
12:53
Earnings
Notable companies reporting after market close »

Notable companies…

MU

Micron

$39.75

-0.63 (-1.56%)

WSM

Williams-Sonoma

$56.40

-0.39 (-0.69%)

GES

Guess

$22.02

-0.49 (-2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

  • 28

    May

ULTA

Ulta Beauty

$334.29

0.14 (0.04%)

, AMZN

Amazon.com

$1,775.60

13.15 (0.75%)

12:47
03/20/19
03/20
12:47
03/20/19
12:47
Recommendations
Ulta Beauty, Amazon.com, e.l.f. Beauty, Revlon, Estee Lauder, Coty analyst commentary  »

Amazon risk still…

ULTA

Ulta Beauty

$334.29

0.14 (0.04%)

AMZN

Amazon.com

$1,775.60

13.15 (0.75%)

ELF

e.l.f. Beauty

$9.73

0.495 (5.36%)

REV

Revlon

$19.49

1.47 (8.16%)

EL

Estee Lauder

$158.67

-2.03 (-1.26%)

COTY

Coty

$11.42

-0.08 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 26

    Mar

  • 04

    Apr

  • 01

    May

  • 28

    May

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$281.08

-1.4 (-0.50%)

12:43
03/20/19
03/20
12:43
03/20/19
12:43
Periodicals
Trump says tariffs on China could last for long period of time »

President Trump, speaking…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$281.08

-1.4 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$113.52

-0.22 (-0.19%)

12:40
03/20/19
03/20
12:40
03/20/19
12:40
Options
Deal hedge opened in Spark Therapeutics »

Deal hedge opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$19.29

0.07 (0.36%)

, LBTYA

Liberty Global

$26.07

-0.08 (-0.31%)

12:39
03/20/19
03/20
12:39
03/20/19
12:39
Periodicals
EC to issue statement of objections on Vodafone, Liberty deal, Reuters says »

EU antitrust regulators…

VOD

Vodafone

$19.29

0.07 (0.36%)

LBTYA

Liberty Global

$26.07

-0.08 (-0.31%)

LBTYK

Liberty Global

$25.40

-0.06 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$39.81

-0.57 (-1.41%)

, SSNLF

Samsung

$0.00

(0.00%)

12:37
03/20/19
03/20
12:37
03/20/19
12:37
Earnings
Fly Intel: What to watch in Micron's earnings report »

Micron (MU) is scheduled…

MU

Micron

$39.81

-0.57 (-1.41%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 28

    May

VOD

Vodafone

$19.30

0.08 (0.42%)

, LBTYA

Liberty Global

$26.03

-0.12 (-0.46%)

12:35
03/20/19
03/20
12:35
03/20/19
12:35
Periodicals
Breaking Periodicals news story on Vodafone, Liberty Global »

EC to issue statement of…

VOD

Vodafone

$19.30

0.08 (0.42%)

LBTYA

Liberty Global

$26.03

-0.12 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$281.11

-1.37 (-0.48%)

, SPX

S&P 500

$0.00

(0.00%)

12:34
03/20/19
03/20
12:34
03/20/19
12:34
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Trump says tariffs to…

SPY

SPDR S&P 500 ETF Trust

$281.11

-1.37 (-0.48%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALLY

Ally Financial

$26.57

-0.29 (-1.08%)

12:30
03/20/19
03/20
12:30
03/20/19
12:30
Options
Aggressive call buy in Ally Financial »

Aggressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 18

    Apr

  • 28

    May

MSFT

Microsoft

$117.41

-0.31 (-0.26%)

, NTDOY

Nintendo

$0.00

(0.00%)

12:25
03/20/19
03/20
12:25
03/20/19
12:25
Periodicals
Former Microsoft exclusive 'Cuphead' coming to Nintendo Switch, Verge says »

Indie video game…

MSFT

Microsoft

$117.41

-0.31 (-0.26%)

NTDOY

Nintendo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

LB

L Brands

$27.53

-0.665 (-2.36%)

12:25
03/20/19
03/20
12:25
03/20/19
12:25
Options
L Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 23

    May

NTNX

Nutanix

$39.18

0.405 (1.04%)

12:25
03/20/19
03/20
12:25
03/20/19
12:25
Conference/Events
Nutanix to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

  • 04

    Apr

  • 09

    Jul

EA

Electronic Arts

$96.97

-0.54 (-0.55%)

, GOOG

Alphabet

$1,206.40

6.69 (0.56%)

12:20
03/20/19
03/20
12:20
03/20/19
12:20
Recommendations
Electronic Arts, Alphabet, Alphabet Class A, Microsoft, Sony analyst commentary  »

Buckingham Neutral on…

EA

Electronic Arts

$96.97

-0.54 (-0.55%)

GOOG

Alphabet

$1,206.40

6.69 (0.56%)

GOOGL

Alphabet Class A

$1,210.03

6.9 (0.57%)

MSFT

Microsoft

$117.34

-0.38 (-0.32%)

SNE

Sony

$43.20

-2.3 (-5.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
03/20/19
03/20
12:17
03/20/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
03/20/19
03/20
12:16
03/20/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$46.07

-1.09 (-2.31%)

12:15
03/20/19
03/20
12:15
03/20/19
12:15
Options
CBS put volume heavy and directionally bearish »

Bearish flow noted in CBS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

12:15
03/20/19
03/20
12:15
03/20/19
12:15
General news
Oil Action: WTI crude »

Oil Action: WTI crude has…

SQ

Square

$74.18

-2.56 (-3.34%)

12:06
03/20/19
03/20
12:06
03/20/19
12:06
Hot Stocks
Square announces new revamped Square Online Store and Square for retail »

Square announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDP

Fresh Del Monte

$27.47

-0.36 (-1.29%)

12:04
03/20/19
03/20
12:04
03/20/19
12:04
Hot Stocks
Fresh Del Monte announces resignation of CFO »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

AMZN

Amazon.com

$1,778.51

16.06 (0.91%)

, DOMO

Domo

$43.20

-0.76 (-1.73%)

12:02
03/20/19
03/20
12:02
03/20/19
12:02
Hot Stocks
Domo announces integration with Amazon SageMaker »

Domo (DOMO) announced a…

AMZN

Amazon.com

$1,778.51

16.06 (0.91%)

DOMO

Domo

$43.20

-0.76 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 26

    Mar

  • 04

    Apr

  • 10

    Apr

FDX

FedEx

$172.31

-9.19 (-5.06%)

, GOOGL

Alphabet Class A

$1,212.82

9.69 (0.81%)

12:01
03/20/19
03/20
12:01
03/20/19
12:01
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have declined in…

FDX

FedEx

$172.31

-9.19 (-5.06%)

GOOGL

Alphabet Class A

$1,212.82

9.69 (0.81%)

GOOG

Alphabet

$1,209.05

9.34 (0.78%)

DIS

Disney

$110.34

0.365 (0.33%)

TFCF

21st Century Fox

$49.61

(0.00%)

NVRO

Nevro

$59.90

15.14 (33.82%)

GIS

General Mills

$49.18

1.94 (4.11%)

TDC

Teradata

$45.31

-3.02 (-6.25%)

SCS

Steelcase

$15.66

-1.825 (-10.44%)

TME

Tencent Music

$16.98

-1.67 (-8.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 27

    Mar

  • 01

    Apr

  • 02

    Apr

  • 04

    Apr

  • 11

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 14

    May

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Oct

CEL

Cellcom Israel

$3.78

-0.29 (-7.13%)

12:00
03/20/19
03/20
12:00
03/20/19
12:00
Hot Stocks
Cellcom Israel falls -7.3% »

Cellcom Israel is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.